Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, ...

All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective ...

Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the ...

Innovative application of an existing drug offers promising alternative treatment to traditional chemotherapy for patients with appendix cancer.

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...

After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer ...

Catherine, Princess of Wales, was diagnosed with cancer earlier this year ... and with that, a new perspective on everything. "This time has above all reminded (Prince) William and me to reflect ...

Israelis Were Surprised to Discover Sinwar’s Body After Shooting Stopped The soldiers who killed Yahya Sinwar, a major target of Israel’s military campaign in Gaza, had not expected to run ...

From manufacturing vital drugs to driving research to raising funds and awareness, leaders like AstraZeneca, Ford and Estée Lauder are having an impact ...

Vyloy is the first CLDN 18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.